InflaRx

97 articles about InflaRx

• InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/9/2021

  InflaRx will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually.

• InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

  9/8/2021

  InflaRx N.V. announces its plan to proceed with a pivotal development program for vilobelimab in Hidradenitis Suppurativa after a successful Type A meeting with the US Food and Drug Administration and receipt of the official meeting minutes.

• InflaRx to Present at the BTIG Virtual Biotechnology Conference

  8/6/2021

  InflaRx will present at the BTIG Virtual Biotechnology Conference on August 10.

• InflaRx Reports Second Quarter 2021 Financial & Operating Results

  8/5/2021

  InflaRx announced today financial and operating results for the three and six months ended June 30, 2021.

• InflaRx to Present at the Raymond James Human Health Innovation Conference

  6/17/2021

  InflaRx N.V. will present virtually at the Raymond James Human Health Innovation Conference being held June 21-23, 2021.

• Tony Gibney Joins InflaRx Board of Directors

  5/21/2021

  InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced Mr. Tony Gibney has been appointed as a Non-Executive Director to the Board of Directors at InflaRx.  

• InflaRx Reports First Quarter 2021 Financial & Operating Results

  5/12/2021

  Inflarx announced today financial results for the three months ended March 31, 2021.

• InflaRx Reports Full Year 2020 Financial & Operating Results

  3/25/2021

  Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1 2021

• InflaRx to Present at Upcoming Investor Conferences

  3/3/2021

  InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two upcoming virtual investor conferences. H.C. Wainwright Global Life Sciences Conference March 9-10, 2021

• InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants

  2/24/2021

  InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that it has commenced an underwritten public offering of common shares of the Company.

• InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference

  2/11/2021

  InflaRx (Nasdaq: IFRX), today announced the presentation of new data with vilobelimab (IFX-1), a first-in-class anti-C5a antibody, demonstrating significantly elevated baseline C5a levels in moderate and severe Hurley Stage II and III hidradenitis suppurativa (HS) patients compared to healthy volunteers.

• InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference

  1/7/2021

  InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2021. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will give a corporate presentation on Thursday, January 14 th at 7:30 am EST (1:30 pm CET) . A live audio w

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer

  9/17/2020

  InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced two management appointments. Effective October 1, 2020, Thomas Taapken, Ph.D. will join InflaRx as Chief Financial Officer. Jordan Zwick has been promoted to Chief Strategy Office

• 

  BioSpace Global Roundup, Sept. 17

  9/17/2020

  Companies from across the globe provide updates on their businesses and pipelines.

• InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia

  9/14/2020

  First site initiated for enrollment in the Netherlands Regulatory approval granted to start trial in Germany Additional sites to be added in the US, EU and other regions Encouraging Phase II data accepted for publication in The Lancet Rheumatology JENA, Germany, Sept. 14, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the start of the global Phase III

• InflaRx to Present at Upcoming Virtual Investor Events

  8/6/2020

  InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at several upcoming virtual investor events in August and September as follows: BTIG Virtual Biotechnology Conference: August 10 th – 11 th A BTIG analyst will host a fireside chat with Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, to discuss the Com

• InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia

  7/21/2020

  50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trial Subject to regulatory approval, a randomized, double-blinded, placebo-controlled, multinational Phase III part of the trial will be initiated Primary endpoint of the planned Phase III part to be 28-day all-cause mortality       

• InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19

  6/17/2020

  IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in patients with severe COVID-19 pneumonia

• 

  Biopharma Update on the Novel Coronavirus: June 17

  6/17/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.